Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2010. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding share allocations for Non-Executive Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of director share transactions rather than a financial performance report.
Material Changes
On September 30, 2010, Non-Executive Directors were provisionally allocated awards over Ordinary shares and American Depository Shares (ADSs) for the service period of July 1, 2010, to September 30, 2010. The allocation price was £12.57 per Ordinary share and $39.77 per ADS. These allocations were notified to the Company and Directors on October 1, 2010.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It strictly details compliance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Non-Executive Directors received share awards for the Q3 2010 service period.
- Allocation prices were set at £12.57 per Ordinary share and $39.77 per ADS.
- Specific share counts were allocated to directors including Sir Christopher Gent (2,684.96 Ordinary Shares) and Mr. Lawrence Culp (769.71 ADSs).
- This filing does not contain financial performance data for the period.